Tobacco and COPD: presenting the World Health Organization (WHO) Tobacco Knowledge Summary.
Chronic obstructive pulmonary disease
Smoking
Smoking cessation
Tobacco control
Journal
Respiratory research
ISSN: 1465-993X
Titre abrégé: Respir Res
Pays: England
ID NLM: 101090633
Informations de publication
Date de publication:
11 Sep 2024
11 Sep 2024
Historique:
received:
28
06
2024
accepted:
25
08
2024
medline:
12
9
2024
pubmed:
12
9
2024
entrez:
11
9
2024
Statut:
epublish
Résumé
The WHO recently published a Tobacco Knowledge Summary (TKS) synthesizing current evidence on tobacco and COPD, aiming to raise awareness among a broad audience of health care professionals. Furthermore, it can be used as an advocacy tool in the fight for tobacco control and prevention of tobacco-related disease. This article builds on the evidence presented in the TKS, with a greater level of detail intended for a lung-specialist audience. Pulmonologists have a vital role to play in advocating for the health of their patients and the wider population by sharing five key messages: (1) Smoking is the leading cause of COPD in high-income countries, contributing to approximately 70% of cases. Quitting tobacco is an essential step toward better lung health. (2) People with COPD face a significantly higher risk of developing lung cancer. Smoking cessation is a powerful measure to reduce cancer risk. (3) Cardiovascular disease, lung cancer and type-2 diabetes are common comorbidities in people with COPD. Quitting smoking not only improves COPD management, but also reduces the risk of developing these coexisting conditions. (4) Tobacco smoke also significantly impacts children's lung growth and development, increasing the risk of respiratory infections, asthma and up to ten other conditions, and COPD later in life. Governments should implement effective tobacco control measures to protect vulnerable populations. (5) The tobacco industry's aggressive strategies in the marketing of nicotine delivery systems and all tobacco products specifically target children, adolescents, and young adults. Protecting our youth from these harmful tactics is a top priority.
Identifiants
pubmed: 39261873
doi: 10.1186/s12931-024-02961-5
pii: 10.1186/s12931-024-02961-5
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
338Informations de copyright
© 2024. The Author(s).
Références
Chronic obstructive pulmonary disease (COPD). Key facts.: World Health Organization. 2023 [updated 16 March 2023. https://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-(copd ).
Fabbri LM, Celli BR, Agusti A, Criner GJ, Dransfield MT, Divo M, et al. COPD and multimorbidity: recognising and addressing a syndemic occurrence. Lancet Respir Med. 2023;11(11):1020–34.
pubmed: 37696283
doi: 10.1016/S2213-2600(23)00261-8
Global Strategy for Prevention. Diagnosis and management of COPD: 2023 report. Fontana: Global Initiative for Chronic Obstructive Lung Disease; 2023.
McDonough JE, Yuan R, Suzuki M, Seyednejad N, Elliott WM, Sanchez PG, et al. Small-airway obstruction and Emphysema in Chronic Obstructive Pulmonary Disease. N Engl J Med. 2011;365(17):1567–75.
pubmed: 22029978
pmcid: 3238466
doi: 10.1056/NEJMoa1106955
Hogg JC, Timens W. The pathology of chronic obstructive pulmonary disease. Annu Rev Pathol. 2009;4:435–59.
pubmed: 18954287
doi: 10.1146/annurev.pathol.4.110807.092145
Eapen MS, Hansbro PM, Larsson-Callerfelt AK, Jolly MK, Myers S, Sharma P, et al. Chronic obstructive Pulmonary Disease and Lung Cancer: underlying pathophysiology and New Therapeutic modalities. Drugs. 2018;78(16):1717–40.
pubmed: 30392114
doi: 10.1007/s40265-018-1001-8
Atto B, Eapen MS, Sharma P, Frey U, Ammit AJ, Markos J, et al. New therapeutic targets for the prevention of infectious acute exacerbations of COPD: role of epithelial adhesion molecules and inflammatory pathways. Clin Sci (Lond). 2019;133(14):1663–703.
pubmed: 31346069
doi: 10.1042/CS20181009
Park SC, Kim DW, Park EC, Shin CS, Rhee CK, Kang YA, et al. Mortality of patients with chronic obstructive pulmonary disease: a nationwide populationbased cohort study. Korean J Intern Med. 2019;34(6):1272–8.
pubmed: 31610634
pmcid: 6823577
doi: 10.3904/kjim.2017.428
Sin DD, Anthonisen NR, Soriano JB, Agusti AG. Mortality in COPD: role of comorbidities. Eur Respir J. 2006;28(6):1245.
pubmed: 17138679
doi: 10.1183/09031936.00133805
Adeloye D, Song P, Zhu Y, Campbell H, Sheikh A, Rudan I, et al. Global, regional, and national prevalence of, and risk factors for, chronic obstructive pulmonary disease (COPD) in 2019: a systematic review and modelling analysis. Lancet Respir Med. 2022;10(5):447–58.
pubmed: 35279265
pmcid: 9050565
doi: 10.1016/S2213-2600(21)00511-7
Safiri S, Carson-Chahhoud K, Noori M, Nejadghaderi SA, Sullman MJM, Ahmadian Heris J, et al. Burden of chronic obstructive pulmonary disease and its attributable risk factors in 204 countries and territories, 1990–2019: results from the global burden of Disease Study 2019. BMJ. 2022;378:e069679.
pubmed: 35896191
pmcid: 9326843
doi: 10.1136/bmj-2021-069679
Christenson SA, Smith BM, Bafadhel M, Putcha N. Chronic obstructive pulmonary disease. Lancet. 2022;399(10342):2227–42.
pubmed: 35533707
doi: 10.1016/S0140-6736(22)00470-6
Borgerding M, Klus H. Analysis of complex mixtures–cigarette smoke. Exp Toxicol Pathol. 2005;57(Suppl 1):43–73.
pubmed: 16092717
doi: 10.1016/j.etp.2005.05.010
What is in a cigarette? American Lung Association. 2023. https://www.lung.org/quit-smoking/smoking-facts/whats-in-a-cigarette
Lugg ST, Scott A, Parekh D, Naidu B, Thickett DR. Cigarette smoke exposure and alveolar macrophages: mechanisms for lung disease. Thorax. 2022;77(1):94–101.
pubmed: 33986144
doi: 10.1136/thoraxjnl-2020-216296
Maung TZ, Bishop JE, Holt E, Turner AM, Pfrang C. Indoor air Pollution and the health of vulnerable groups: a systematic review focused on Particulate Matter (PM), volatile Organic compounds (VOCs) and their effects on children and people with Pre-existing Lung Disease. Int J Environ Res Public Health. 2022;19(14).
Pathak U, Gupta NC, Suri JC. Risk of COPD due to indoor air pollution from biomass cooking fuel: a systematic review and meta-analysis. Int J Environ Health Res. 2020;30(1):75–88.
pubmed: 30754998
doi: 10.1080/09603123.2019.1575951
Mannino DM, Buist AS. Global burden of COPD: risk factors, prevalence, and future trends. Lancet. 2007;370(9589):765–73.
pubmed: 17765526
doi: 10.1016/S0140-6736(07)61380-4
Khalequzzaman M, Kamijima M, Sakai K, Hoque BA, Nakajima T. Indoor air pollution and the health of children in biomass- and fossil-fuel users of Bangladesh: situation in two different seasons. Environ Health Prev Med. 2010;15(4):236–43.
pubmed: 21432551
pmcid: 2886889
doi: 10.1007/s12199-009-0133-6
Gordon SB, Bruce NG, Grigg J, Hibberd PL, Kurmi OP, Lam KB, et al. Respiratory risks from household air pollution in low and middle income countries. Lancet Respir Med. 2014;2(10):823–60.
pubmed: 25193349
pmcid: 5068561
doi: 10.1016/S2213-2600(14)70168-7
Anderson DO, Ferris BG Jr. Role of tobacco smoking in the causation of chronic respiratory disease. N Engl J Med. 1962;267:787–94.
pubmed: 14012834
doi: 10.1056/NEJM196210182671601
Nicolaou L, Checkley W. Differences between cigarette smoking and biomass smoke exposure: an in silico comparative assessment of particulate deposition in the lungs. Environ Res. 2021;197:111116.
pubmed: 33823195
pmcid: 8187290
doi: 10.1016/j.envres.2021.111116
Martinez FJ, Curtis JL, Sciurba F, Mumford J, Giardino ND, Weinmann G, et al. Sex differences in severe pulmonary emphysema. Am J Respir Crit Care Med. 2007;176(3):243–52.
pubmed: 17431226
pmcid: 1994221
doi: 10.1164/rccm.200606-828OC
Downs SH, Brandli O, Zellweger JP, Schindler C, Kunzli N, Gerbase MW, et al. Accelerated decline in lung function in smoking women with airway obstruction: SAPALDIA 2 cohort study. Respir Res. 2005;6(1):45.
pubmed: 15918902
pmcid: 1177989
doi: 10.1186/1465-9921-6-45
Silverman EK, Weiss ST, Drazen JM, Chapman HA, Carey V, Campbell EJ, et al. Gender-related differences in severe, early-onset chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000;162(6):2152–8.
pubmed: 11112130
doi: 10.1164/ajrccm.162.6.2003112
Camp PG, Coxson HO, Levy RD, Pillai SG, Anderson W, Vestbo J, et al. Sex differences in emphysema and airway disease in smokers. Chest. 2009;136(6):1480–8.
pubmed: 19617404
doi: 10.1378/chest.09-0676
Dransfield MT, Davis JJ, Gerald LB, Bailey WC. Racial and gender differences in susceptibility to tobacco smoke among patients with chronic obstructive pulmonary disease. Respir Med. 2006;100(6):1110–6.
pubmed: 16236491
doi: 10.1016/j.rmed.2005.09.019
Harmful. and potentially harmful constituents in tobacco products and tobacco smoke; established list. US Food and Drug Administration Fed Regist. 2012;77(64):20034–7.
Pappas RS. Toxic elements in tobacco and in cigarette smoke: inflammation and sensitization. Metallomics. 2011;3(11):1181–98.
pubmed: 21799956
doi: 10.1039/c1mt00066g
Huang MF, Lin WL, Ma YC. A study of reactive oxygen species in mainstream of cigarette. Indoor Air. 2005;15(2):135–40.
pubmed: 15737156
doi: 10.1111/j.1600-0668.2005.00330.x
Djordjevic MV, Doran KA. Nicotine content and delivery across tobacco products. Handb Exp Pharmacol. 2009;192:61–82.
doi: 10.1007/978-3-540-69248-5_3
Addictiveness and Attractiveness of Tobacco Additives Brussels. 2010 [updated 12 November. https://ec.europa.eu/health/scientific_committees/emerging/docs/scenihr_o_031.pdf
Rabinoff M, Caskey N, Rissling A, Park C. Pharmacological and chemical effects of cigarette additives. Am J Public Health. 2007;97(11):1981–91.
pubmed: 17666709
pmcid: 2040350
doi: 10.2105/AJPH.2005.078014
Salvi S. Tobacco smoking and environmental risk factors for chronic obstructive pulmonary disease. Clin Chest Med. 2014;35(1):17–27.
pubmed: 24507834
doi: 10.1016/j.ccm.2013.09.011
Wiegman CH, Li F, Ryffel B, Togbe D, Chung KF. Oxidative stress in ozone-Induced chronic lung inflammation and Emphysema: a facet of Chronic Obstructive Pulmonary Disease. Front Immunol. 2020;11:1957.
pubmed: 32983127
pmcid: 7492639
doi: 10.3389/fimmu.2020.01957
Gunen H, Tarraf H, Nemati A, Al Ghobain M, Al Mutairi S, Aoun Bacha Z. Waterpipe tobacco smoking. Tuberk Toraks. 2016;64(1):94–6.
pubmed: 27266294
doi: 10.5578/tt.13935
She J, Yang P, Wang Y, Qin X, Fan J, Wang Y, et al. Chinese water-pipe smoking and the risk of COPD. Chest. 2014;146(4):924–31.
pubmed: 24557573
doi: 10.1378/chest.13-1499
Smoking and Tobacco Use. Fast facts and fact sheets 2021. Atlanta (GE)2023 https://www.cdc.gov/tobacco/data_statistics/fact_sheets/fast_facts/index.htm
Santoro A, Tomino C, Prinzi G, Lamonaca P, Cardaci V, Fini M, et al. Tobacco Smoking: risk to develop addiction, Chronic Obstructive Pulmonary Disease, and Lung Cancer. Recent Pat Anticancer Drug Discov. 2019;14(1):39–52.
pubmed: 30605063
doi: 10.2174/1574892814666190102122848
Papke RL. The many enigmas of nicotine. Adv Pharmacol. 2024;99:327–54.
pubmed: 38467485
doi: 10.1016/bs.apha.2023.08.001
Agustí A, Hogg JC. Update on the Pathogenesis of Chronic Obstructive Pulmonary Disease. N Engl J Med. 2019;381(13):1248–56.
pubmed: 31553836
doi: 10.1056/NEJMra1900475
Brightling C, Greening N. Airway inflammation in COPD: progress to precision medicine. Eur Respir J. 2019;54(2).
Eapen MS, McAlinden K, Tan D, Weston S, Ward C, Muller HK, et al. Profiling cellular and inflammatory changes in the airway wall of mild to moderate COPD. Respirology. 2017;22(6):1125–32.
pubmed: 28326668
doi: 10.1111/resp.13021
Eapen MS, Hansbro PM, McAlinden K, Kim RY, Ward C, Hackett TL, et al. Abnormal M1/M2 macrophage phenotype profiles in the small airway wall and lumen in smokers and chronic obstructive pulmonary disease (COPD). Sci Rep. 2017;7(1):13392.
pubmed: 29042607
pmcid: 5645352
doi: 10.1038/s41598-017-13888-x
Liu G, Haw TJ, Starkey MR, Philp AM, Pavlidis S, Nalkurthi C, et al. TLR7 promotes smoke-induced experimental lung damage through the activity of mast cell tryptase. Nat Commun. 2023;14(1):7349.
pubmed: 37963864
pmcid: 10646046
doi: 10.1038/s41467-023-42913-z
O’Beirne SL, Kikkers SA, Oromendia C, Salit J, Rostmai MR, Ballman KV, et al. Alveolar macrophage immunometabolism and lung function impairment in Smoking and Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2020;201(6):735–9.
pubmed: 31751151
pmcid: 7068819
doi: 10.1164/rccm.201908-1683LE
Stoller JK, Aboussouan LS. α1-antitrypsin deficiency. Lancet. 2005;365(9478):2225–36.
pubmed: 15978931
doi: 10.1016/S0140-6736(05)66781-5
Shrine N, Guyatt AL, Erzurumluoglu AM, Jackson VE, Hobbs BD, Melbourne CA, et al. New genetic signals for lung function highlight pathways and chronic obstructive pulmonary disease associations across multiple ancestries. Nat Genet. 2019;51(3):481–93.
pubmed: 30804560
pmcid: 6397078
doi: 10.1038/s41588-018-0321-7
Obeidat Me, Hao K, Bossé Y, Nickle DC, Nie Y, Postma DS, et al. Molecular mechanisms underlying variations in lung function: a systems genetics analysis. Lancet Respiratory Med. 2015;3(10):782–95.
doi: 10.1016/S2213-2600(15)00380-X
Zhou JJ, Cho MH, Castaldi PJ, Hersh CP, Silverman EK, Laird NM. Heritability of chronic obstructive pulmonary disease and related phenotypes in smokers. Am J Respir Crit Care Med. 2013;188(8):941–7.
pubmed: 23972146
pmcid: 3826281
doi: 10.1164/rccm.201302-0263OC
Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. Eur Respir J. 2009;33(5):1165.
pubmed: 19407051
doi: 10.1183/09031936.00128008
André S, Conde B, Fragoso E, Boléo-Tomé JP, Areias V, Cardoso J. COPD and Cardiovascular Disease. Pulmonology. 2019;25(3):168–76.
pubmed: 30527374
doi: 10.1016/j.pulmoe.2018.09.006
Bhattarai P, Lu W, Gaikwad AV, Dey S, Chia C, Larby J et al. Arterial remodelling in smokers and in patients with small airway disease and COPD: implications for lung physiology and early origins of pulmonary hypertension. ERJ Open Res. 2022;8(4).
Padeletti M, Jelic S, LeJemtel TH. Coexistent chronic obstructive pulmonary disease and heart failure in the elderly. Int J Cardiol. 2008;125(2):209–15.
pubmed: 18221802
doi: 10.1016/j.ijcard.2007.12.001
Barberà JA. Mechanisms of development of chronic obstructive pulmonary disease-associated pulmonary hypertension. Pulm Circ. 2013;3(1):160–4.
pubmed: 23662194
pmcid: 3641725
doi: 10.4103/2045-8932.109949
Santos S, Peinado VI, Ramirez J, Melgosa T, Roca J, Rodriguez-Roisin R, et al. Characterization of pulmonary vascular remodelling in smokers and patients with mild COPD. Eur Respir J. 2002;19(4):632–8.
pubmed: 11998991
doi: 10.1183/09031936.02.00245902
Bhattarai P, Lu W, Hardikar A, Dey S, Gaikwad AV, Shahzad AM et al. Endothelial to mesenchymal transition is an active process in smokers and patients with early COPD contributing to pulmonary arterial pathology. ERJ Open Res. 2024;10(1).
Chaouat A, Naeije R, Weitzenblum E. Pulmonary hypertension in COPD. Eur Respir J. 2008;32(5):1371.
pubmed: 18978137
doi: 10.1183/09031936.00015608
Nathan SD, Barbera JA, Gaine SP, Harari S, Martinez FJ, Olschewski H et al. Pulmonary hypertension in chronic lung disease and hypoxia. Eur Respir J. 2019;53(1).
Fiorentino G, Esquinas AM, Annunziata A. Exercise and Chronic Obstructive Pulmonary Disease (COPD). Adv Exp Med Biol. 2020;1228:355–68.
pubmed: 32342470
doi: 10.1007/978-981-15-1792-1_24
Henrot P, Dupin I, Schilfarth P, Esteves P, Blervaque L, Zysman M et al. Main pathogenic mechanisms and recent advances in COPD Peripheral skeletal muscle wasting. Int J Mol Sci. 2023;24(7).
Osteoporosis prevention. Diagnosis, and therapy. JAMA. 2001;285(6):785–95.
doi: 10.1001/jama.285.6.785
Cully JA, Graham DP, Stanley MA, Ferguson CJ, Sharafkhaneh A, Souchek J, et al. Quality of life in patients with chronic obstructive pulmonary disease and comorbid anxiety or depression. Psychosomatics. 2006;47(4):312–9.
pubmed: 16844889
doi: 10.1176/appi.psy.47.4.312
Polkey MI, Moxham J. Attacking the disease spiral in chronic obstructive pulmonary disease. Clin Med. 2006;6(2):190–6.
doi: 10.7861/clinmedicine.6-2-190
Sin DD, Man JP, Man SFP. The risk of osteoporosis in caucasian men and women with obstructive airways disease. Am J Med. 2003;114(1):10–4.
pubmed: 12543283
doi: 10.1016/S0002-9343(02)01297-4
Li Y, Gao H, Zhao L, Wang J. Osteoporosis in COPD patients: risk factors and pulmonary rehabilitation. Clin Respir J. 2022;16(7):487–96.
pubmed: 35688435
pmcid: 9329018
doi: 10.1111/crj.13514
Pompe E, Bartstra J, Verhaar HJ, de Koning HJ, van der Aalst CM, Oudkerk M, et al. Bone density loss on computed tomography at 3-year follow-up in current compared to former male smokers. Eur J Radiol. 2017;89:177–81.
pubmed: 28267536
doi: 10.1016/j.ejrad.2017.02.011
Lau RY, Guo X. A review on current osteoporosis research: with special focus on disuse bone loss. J Osteoporos. 2011;2011:293808.
pubmed: 21876833
pmcid: 3160709
doi: 10.4061/2011/293808
Graat-Verboom L, Wouters EF, Smeenk FW, van den Borne BE, Lunde R, Spruit MA. Current status of research on osteoporosis in COPD: a systematic review. Eur Respir J. 2009;34(1):209–18.
pubmed: 19567604
doi: 10.1183/09031936.50130408
Okazaki R, Watanabe R, Inoue D. Osteoporosis Associated with Chronic Obstructive Pulmonary Disease. J Bone Metab. 2016;23(3):111–20.
pubmed: 27622174
pmcid: 5018603
doi: 10.11005/jbm.2016.23.3.111
Inoue D, Watanabe R, Okazaki R. COPD and osteoporosis: links, risks, and treatment challenges. Int J Chron Obstruct Pulmon Dis. 2016;11:637–48.
pubmed: 27099481
pmcid: 4820217
doi: 10.2147/COPD.S79638
Homętowska H, Klekowski J, Świątoniowska-Lonc N, Jankowska-Polańska B, Chabowski M. Fatigue, Depression, and anxiety in patients with COPD, asthma and Asthma-COPD overlap. J Clin Med. 2022;11(24).
Kunik ME, Roundy K, Veazey C, Souchek J, Richardson P, Wray NP, et al. Surprisingly high prevalence of anxiety and Depression in Chronic Breathing disorders. Chest. 2005;127(4):1205–11.
pubmed: 15821196
García-Sanz MT, González-Barcala FJ. COPD is more than just lung function: Let’s not forget depression. Arch Bronconeumol. 2021;57(8):519–20.
pubmed: 34053892
doi: 10.1016/j.arbr.2021.05.023
Martínez-Gestoso S, García-Sanz MT, Carreira JM, Salgado FJ, Calvo-Álvarez U, Doval-Oubiña L, et al. Impact of anxiety and depression on the prognosis of copd exacerbations. BMC Pulm Med. 2022;22(1):169.
pubmed: 35488330
doi: 10.1186/s12890-022-01934-y
Willgoss TG, Yohannes AM. Anxiety disorders in patients with COPD: a systematic review. Respir Care. 2013;58(5):858–66.
pubmed: 22906542
doi: 10.4187/respcare.01862
Yohannes AM, Alexopoulos GS. Depression and anxiety in patients with COPD. Eur Respir Rev. 2014;23(133):345–9.
pubmed: 25176970
pmcid: 4523084
doi: 10.1183/09059180.00007813
Benson VS, Müllerová H, Vestbo J, Wedzicha JA, Patel A, Hurst JR. Associations between gastro-oesophageal reflux, its management and exacerbations of chronic obstructive pulmonary disease. Respir Med. 2015;109(9):1147–54.
pubmed: 26166017
doi: 10.1016/j.rmed.2015.06.009
Pandolfino JE, Kahrilas PJ. Smoking and gastro-oesophageal reflux disease. Eur J Gastroenterol Hepatol. 2000;12(8):837–42.
pubmed: 10958210
doi: 10.1097/00042737-200012080-00002
Lee AL, Goldstein RS. Gastroesophageal reflux disease in COPD: links and risks. Int J Chron Obstruct Pulmon Dis. 2015;10:1935–49.
pubmed: 26392769
pmcid: 4574848
doi: 10.2147/COPD.S77562
Ingebrigtsen TS, Marott JL, Vestbo J, Nordestgaard BG, Hallas J, Lange P. Gastro-esophageal reflux disease and exacerbations in chronic obstructive pulmonary disease. Respirology. 2015;20(1):101–7.
pubmed: 25297724
doi: 10.1111/resp.12420
Dore MP, Maragkoudakis E, Fraley K, Pedroni A, Tadeu V, Realdi G, et al. Diet, lifestyle and gender in gastro-esophageal reflux disease. Dig Dis Sci. 2008;53(8):2027–32.
pubmed: 18030622
doi: 10.1007/s10620-007-0108-7
Sasaki T, Nakayama K, Yasuda H, Yoshida M, Asamura T, Ohrui T, et al. A Randomized, single-blind study of Lansoprazole for the Prevention of exacerbations of Chronic Obstructive Pulmonary Disease in older patients. J Am Geriatr Soc. 2009;57(8):1453–7.
pubmed: 19515110
doi: 10.1111/j.1532-5415.2009.02349.x
Barnes PJ, Burney PG, Silverman EK, Celli BR, Vestbo J, Wedzicha JA, et al. Chronic obstructive pulmonary disease. Nat Rev Dis Primers. 2015;1:15076.
pubmed: 27189863
doi: 10.1038/nrdp.2015.76
de Torres JP, Marin JM, Casanova C, Cote C, Carrizo S, Cordoba-Lanus E, et al. Lung cancer in patients with chronic obstructive pulmonary disease– incidence and predicting factors. Am J Respir Crit Care Med. 2011;184(8):913–9.
pubmed: 21799072
doi: 10.1164/rccm.201103-0430OC
Tahery N, Zarea K, Cheraghi M, Hatamzadeh N, Farhadi M, Dobaradarn S, et al. Chronic obstructive Pulmonary Disease (COPD) and Air Pollution: a review. Jundishapur J Chronic Dis Care. 2021;10(1):e110273.
doi: 10.5812/jjcdc.110273
Lu W, Eapen MS, Hardikar A, Chia C, Robertson I, Singhera GK et al. Epithelial-mesenchymal transition changes in nonsmall cell lung cancer patients with early COPD. ERJ Open Res. 2023;9(6).
Gohy ST, Hupin C, Fregimilicka C, Detry BR, Bouzin C, Gaide Chevronay H, et al. Imprinting of the COPD airway epithelium for dedifferentiation and mesenchymal transition. Eur Respir J. 2015;45(5):1258–72.
pubmed: 25745049
doi: 10.1183/09031936.00135814
Milara J, Peiró T, Serrano A, Cortijo J. Epithelial to mesenchymal transition is increased in patients with COPD and induced by cigarette smoke. Thorax. 2013;68(5):410–20.
pubmed: 23299965
doi: 10.1136/thoraxjnl-2012-201761
Karacosta LG, Anchang B, Ignatiadis N, Kimmey SC, Benson JA, Shrager JB, et al. Mapping lung cancer epithelial-mesenchymal transition states and trajectories with single-cell resolution. Nat Commun. 2019;10(1):5587.
pubmed: 31811131
pmcid: 6898514
doi: 10.1038/s41467-019-13441-6
Karacosta LG, Pancirer D, Preiss JS, Benson JA, Trope W, Shrager JB, et al. Phenotyping EMT and MET cellular states in lung cancer patient liquid biopsies at a personalized level using mass cytometry. Sci Rep. 2023;13(1):21781.
pubmed: 38065965
pmcid: 10709404
doi: 10.1038/s41598-023-46458-5
Sohal SS, Soltani A, Reid D, Ward C, Wills KE, Muller HK, et al. A randomized controlled trial of inhaled corticosteroids (ICS) on markers of epithelial-mesenchymal transition (EMT) in large airway samples in COPD: an exploratory proof of concept study. Int J Chron Obstruct Pulmon Dis. 2014;9:533–42.
pubmed: 24920891
pmcid: 4043431
doi: 10.2147/COPD.S63911
Soltani A, Walters EH, Reid DW, Shukla SD, Nowrin K, Ward C, et al. Inhaled corticosteroid normalizes some but not all airway vascular remodeling in COPD. Int J Chron Obstruct Pulmon Dis. 2016;11:2359–67.
pubmed: 27703346
pmcid: 5038570
doi: 10.2147/COPD.S113176
Parimon T, Chien JW, Bryson CL, McDonell MB, Udris EM, Au DH. Inhaled corticosteroids and Risk of Lung Cancer among patients with chronic obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2007;175(7):712–9.
pubmed: 17185647
doi: 10.1164/rccm.200608-1125OC
Ge F, Feng Y, Huo Z, Li C, Wang R, Wen Y, et al. Inhaled corticosteroids and risk of lung cancer among chronic obstructive pulmonary disease patients: a comprehensive analysis of nine prospective cohorts. Transl Lung Cancer Res. 2021;10(3):1266–76.
pubmed: 33889508
pmcid: 8044471
doi: 10.21037/tlcr-20-1126
Tareke AA, Debebe W, Alem A, Bayileyegn NS, Zerfu TA, Ayana AM. Inhaled corticosteroids and the risk of Lung Cancer in Chronic Obstructive Pulmonary Disease patients: a systematic review and Meta-analysis. Pulm Med. 2022;2022:9799858.
pubmed: 36046848
pmcid: 9420625
doi: 10.1155/2022/9799858
Pitre T, Kiflen M, Ho T, Seijo LM, Zeraatkar D, de Torres JP. Inhaled corticosteroids, COPD, and the incidence of lung cancer: a systematic review and dose response meta-analysis. BMC Pulm Med. 2022;22(1):275.
pubmed: 35843928
pmcid: 9290283
doi: 10.1186/s12890-022-02072-1
Park JE, Lee E, Singh D, Kim EK, Park B, Park JH. The effect of inhaler prescription on the development of lung cancer in COPD: a nationwide population-based study. Respir Res. 2024;25(1):229.
pubmed: 38822332
pmcid: 11140980
doi: 10.1186/s12931-024-02838-7
Diver WR, Jacobs EJ, Gapstur SM. Secondhand smoke exposure in Childhood and Adulthood in Relation to Adult Mortality among Never smokers. Am J Prev Med. 2018;55(3):345–52.
pubmed: 30122215
doi: 10.1016/j.amepre.2018.05.005
Putcha N, Barr RG, Han MK, Woodruff PG, Bleecker ER, Kanner RE, et al. Understanding the impact of second-hand smoke exposure on clinical outcomes in participants with COPD in the SPIROMICS cohort. Thorax. 2016;71(5):411.
pubmed: 26962015
doi: 10.1136/thoraxjnl-2015-207487
Yin P, Jiang CQ, Cheng KK, Lam TH, Lam KH, Miller MR, et al. Passive smoking exposure and risk of COPD among adults in China: the Guangzhou Biobank Cohort Study. Lancet. 2007;370(9589):751–7.
pubmed: 17765524
doi: 10.1016/S0140-6736(07)61378-6
Hecht SS, Hatsukami DK. Smokeless tobacco and cigarette smoking: chemical mechanisms and cancer prevention. Nat Rev Cancer. 2022;22(3):143–55.
pubmed: 34980891
pmcid: 9308447
doi: 10.1038/s41568-021-00423-4
Hatsukami D, Zeller M, Gupta P, Parascandola M, Asma S. Smokeless tobacco and public health: a global perspective. 2014.
Kass AP, Overbeek DL, Chiel LE, Boyer EW, Casey AMH. Case series: adolescent victims of the vaping public health crisis with pulmonary complications. Pediatr Pulmonol. 2020;55(5):1224–36.
pubmed: 32168438
doi: 10.1002/ppul.24729
McAlinden KD, Eapen MS, Lu W, Sharma P, Sohal SS. The rise of electronic nicotine delivery systems and the emergence of electronic-cigarette-driven disease. Am J Physiol Lung Cell Mol Physiol. 2020;319(4):L585–95.
pubmed: 32726146
doi: 10.1152/ajplung.00160.2020
Park JA, Crotty Alexander LE, Christiani DC. Vaping and lung inflammation and Injury. Annu Rev Physiol. 2022;84:611–29.
pubmed: 34724436
doi: 10.1146/annurev-physiol-061121-040014
Bowler RP, Hansel NN, Jacobson S, Graham Barr R, Make BJ, Han MK, et al. Electronic cigarette use in US adults at risk for or with COPD: analysis from two observational cohorts. J Gen Intern Med. 2017;32(12):1315–22.
pubmed: 28884423
pmcid: 5698219
doi: 10.1007/s11606-017-4150-7
Osei AD, Mirbolouk M, Orimoloye OA, Dzaye O, Uddin SMI, Benjamin EJ, et al. Association between E-Cigarette Use and Chronic Obstructive Pulmonary Disease by Smoking Status: behavioral risk factor Surveillance System 2016 and 2017. Am J Prev Med. 2020;58(3):336–42.
pubmed: 31902685
pmcid: 9843649
doi: 10.1016/j.amepre.2019.10.014
Perez MF, Atuegwu NC, Mead EL, Oncken C, Mortensen EM. Adult E-Cigarettes use Associated with a self-reported diagnosis of COPD. Int J Environ Res Public Health. 2019; 16(20).
Wang JB, Olgin JE, Nah G, Vittinghoff E, Cataldo JK, Pletcher MJ, et al. Cigarette and e-cigarette dual use and risk of cardiopulmonary symptoms in the Health eHeart Study. PLoS ONE. 2018;13(7):e0198681.
pubmed: 30044773
pmcid: 6059385
doi: 10.1371/journal.pone.0198681
Xie Z, Ossip DJ, Rahman I, Li D. Use of Electronic cigarettes and Self-reported chronic obstructive Pulmonary Disease diagnosis in adults. Nicotine Tob Res. 2020;22(7):1155–61.
pubmed: 31830263
doi: 10.1093/ntr/ntz234
Chen DT, Grigg J, Filippidis FT. European Respiratory Society statement on novel nicotine and tobacco products, their role in tobacco control and harm reduction. Eur Respir J. 2024;63(2).
Glantz SA. The cigarette papers. Univ of California; 1996.
Glantz SA. Heated tobacco products: the example of IQOS. Tob Control. 2018;27(Suppl 1):s1.
pubmed: 30352841
doi: 10.1136/tobaccocontrol-2018-054601
Bravo-Gutierrez OA, Falfan-Valencia R, Ramirez-Venegas A, Sansores RH, Ponciano-Rodriguez G, Perez-Rubio G. Lung damage caused by Heated Tobacco Products and Electronic Nicotine Delivery systems: a systematic review. Int J Environ Res Public Health. 2021;18(8).
Leigh NJ, Tran PL, O’Connor RJ, Goniewicz ML. Cytotoxic effects of heated tobacco products (HTP) on human bronchial epithelial cells. Tob Control. 2018;27(Suppl 1):s26–9.
pubmed: 30185530
doi: 10.1136/tobaccocontrol-2018-054317
Sohal SS, Eapen MS, Naidu GMV, Sharma P. IQOS exposure impairs human airway cell homeostasis: direct comparison with traditional cigarette and e-cigarette. ERJ Open Res. 2019;5(1):00159–2018.
pubmed: 30775377
pmcid: 6368999
doi: 10.1183/23120541.00159-2018
Nakama C, Tabuchi T. Use of heated tobacco products by people with chronic diseases: the 2019 JASTIS study. PLoS ONE. 2021;16(11):e0260154.
pubmed: 34793517
pmcid: 8601522
doi: 10.1371/journal.pone.0260154
Glantz SA. PMI’s own in vivo clinical data on biomarkers of potential harm in americans show that IQOS is not detectably different from conventional cigarettes. Tob Control. 2018;27(Suppl 1):s9.
pubmed: 30131374
doi: 10.1136/tobaccocontrol-2018-054413
Tashkin DP. Smoking Cessation in Chronic Obstructive Pulmonary Disease. Semin Respir Crit Care Med. 2015;36(4):491–507.
pubmed: 26238637
doi: 10.1055/s-0035-1555610
Pezzuto A, Carico E. Effectiveness of smoking cessation in smokers with COPD and nocturnal oxygen desaturation: functional analysis. Clin Respir J. 2020;14(1):29–34.
pubmed: 31613417
doi: 10.1111/crj.13096
WHO Package of Essential Noncomunicable (PEN). Disease Interventions for Primary Health Care. World Health Organization; 2020.
WHO Report on the Global Tobacco Epidemic. 2023: protect people from tobacco smoke. Geneva: World Health Organization; 2023.
WHO calls on governments to include smoking cessation in tobacco control strategies. Geneva: World Health Organizition. 2023. https://www.who.int/news/item/06-08-2003-who-calls-on-governments-to-includesmoking-cessation-in-tobacco-control-strategies
United States Public Health Service Office of the Surgeon G, National Center for Chronic Disease P. Health Promotion Office on S, Health. Publications and reports of the Surgeon General. Smoking Cessation: a report of the Surgeon General. Washington (DC): US Department of Health and Human Services; 2020.
Soriano JB, Jenkins C. How should good lung health be defined at the population and individual levels? Eur Respir J. 2023;62(3):2301166.
pubmed: 37690786
doi: 10.1183/13993003.01166-2023
Malone RE. Imagining things otherwise: new endgame ideas for tobacco control. Tob Control. 2010;19(5):349–50.
pubmed: 20876073
doi: 10.1136/tc.2010.039727
Dai X, Gakidou E, Lopez AD. Evolution of the global smoking epidemic over the past half century: strengthening the evidence base for policy action. Tob Control. 2022;31(2):129.
pubmed: 35241576
doi: 10.1136/tobaccocontrol-2021-056535
WHO global report on trends in prevalence of tobacco use. 2000–2030: World Health Organization; 2024 [updated 16 January 2024. https://www.who.int/publications/i/item/9789240088283
Melén E, Faner R, Allinson JP, Bui D, Bush A, Custovic A et al. Lung-function trajectories: relevance and implementation in clinical practice. Lancet. 2024.
Lu W, Aarsand R, Rylance S, Schotte K, Han J, Lebedeva E et al. Tobacco and chronic obstructive pulmonary disease (COPD). WHO; 2023 14 November.
WHO clinical. Treatment guideline for tobacco cessation in adults. Geneva: World Health Organization; 2024.